Nervous System Diseases

All Conditions

Neoplasms

Immune System Diseases

Symptoms and General Pathology

Encephalitis

Anti-N-Methyl-D-Aspartate Receptor Encephalitis

Brain Diseases

Central Nervous System Diseases

Neuroinflammatory Diseases

Syndrome

Paraneoplastic Syndromes

Paraneoplastic Syndromes, Nervous System

Nervous System Neoplasms

Neurodegenerative Diseases

Autoimmune Diseases

Autoimmune Diseases of the Nervous System

All Drugs and Chemicals

Antineoplastic Agents

Antirheumatic Agents

Antibodies

Rituximab

Immunoglobulins

Immunoglobulins, Intravenous

Antineoplastic Agents, Immunological

Immunologic Factors

* 4 Rituximab injections
* 10 IA sessions

10 IA sessions performed in 28 days maximum, using TherasorbTM adsorbers which contain sheep derived polyvalent antihuman-immunoglobulin coupled to SepharoseTM CL-4B.

IA session

Concomitantly, Rituximab will be given each week for 4 weeks (one injection by week +/- 3 days):

* at least 1 day before each IA session
* the last injection will occur after the last session IA (minimum one day after)

Isabelle DESGUERRE, MD, PhD

Aminata TRAORE

Rémi SALOMON, Md, PhD

The purpose of the study is to assess the efficacy of immunoadsorption therapy (IA) on improving the neurological status of severe pediatric anti-NMDAR encephalitis patients.

Anti-NMDA-Receptor (NMDAR) encephalitis, the most frequent autoimmune encephalitis after Acute Demyelinating encephalomyelitis (ADEM), affects children with predominant movement disorders, decline of consciousness, psychiatric symptoms, language dysfunction, seizures, dysautonomic symptoms. The cerebrospinal fluid (CSF) is most often abnormal with lymphocytic pleocytosis, CSF-specific oligoclonal bands with intrathecal synthesis of anti-NMDAR antibodies. Antibody titres in CSF and serum seem correlated with clinical outcome. Early start of immunotherapy has been reported to improve clinical outcome and associated with less relapses. In a recent large series (211 children/577), 77% of the patients were admitted to Intensive Care Unit (ICU) at the beginning. Within the group of children, first-line immunotherapy (95%) consisted of corticosteroids (89%), and/or intravenous immunoglobulins (IgIV) (83%), and/or plasma exchange (28%) with failure in 46%. The second-line immunotherapy consisting in rituximab (24%) and/or cyclophosphamide (16%) was proposed in 32%, and tended to be associated with good outcome (OR=3.35, CI: 0.86-12.98, p=0.081 for 53 children; statistical significance was achieved for the entire population including adults (OR: 2.69, CI: 1.24-5.80, p = 0.012) and less relapses.

In investigators' experience, the clinical benefit of rituximab is delayed over one month, while children go on worsening (50% admitted in ICU) thus claiming for faster removal of the antibodies. Plasma exchange is proposed in most of the series as alternative or combined treatment in the acute stage (first-line immunotherapy); recently, another plasmatherapy, immunoadsorption therapy (IA), has been reported as an efficient therapeutic approach in 11/13 patients. In this retrospective study, patients received a median of 6 IA sessions within a median period of 8 days with relevant clinical improvement. However these encouraging results and investigators' experience in few children need further prospective and standardized evaluation.

In IANMDAR study, each patient will receive 10 IA sessions during 28 days maximum. Rituximab will be given each week for 4 weeks (one injection by week +/- 3 days):

* at least 1 day before each IA session
* the 4 injections should be done before V2 (Day 28 after the inclusion)

To assess the efficacy of IA-therapy at short term, the neurological status of patients will be evaluated before and after the 10 IA sessions using the Pediatric Cerebral Performance Category Scale (PCPCS) and the modified Rankin Scale (mRS).

To assess the efficacy of IA-therapy at long term, patients will have a standardized follow-up during two years including neuropsychological evaluation at 1 year and at 2 years (see below for further details).

Immunoadsorption Therapy in Managing NMDAR Antibodies Encephalitis

Prospective Assessment of Efficacy of Immunoadsorption Therapy in Managing Childhood NMDA-Receptor (NMDAR) Antibodies Encephalitis

at least reduction of 1 point in PCPCS between the two evaluations is expected

at least reduction of 1 point in mRS between the two evaluations is expected

To assess immunoadsorption therapy at short term in pediatric severe anti-NMDAR encephalitis patients

independent ambulation, enteral feeding, responsiveness to simple instructions and verbal communication (first word)

To assess Immunoadsorption therapy at long term

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Immunoadsorption Therapy in Managing NMDAR Antibodies Encephalitis	NCT03274375	Anti-NMDAR Ence...	IA session Rituximab	- 18 Years	Assistance Publique - Hôpitaux de Paris
Immunoadsorption Therapy in Managing NMDAR Antibodies Encephalitis	NCT03274375	Anti-NMDAR Ence...	IA session Rituximab	- 18 Years	Assistance Publique - Hôpitaux de Paris

Spots Global Cancer Trial Database for ia adsorption